358 related articles for article (PubMed ID: 36164415)
1. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Dong R; Yan Y; Zeng X; Lin N; Tan B
Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415
[TBL] [Abstract][Full Text] [Related]
2. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
3. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
Christensen BW; Zaha VG; Awan FT
Expert Rev Hematol; 2022 Apr; 15(4):321-331. PubMed ID: 35437106
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.
Patel JN; Singh J; Ghosh N
Oncotarget; 2024 Jun; 15():355-359. PubMed ID: 38829647
[TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
7. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
8. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
Timofeeva N; Gandhi V
Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
[TBL] [Abstract][Full Text] [Related]
10. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
11. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
12. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
[TBL] [Abstract][Full Text] [Related]
14. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
15. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Lasica M; Tam CS
Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985
[TBL] [Abstract][Full Text] [Related]
16. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Pineda-Gayoso R; Alomar M; Lee DH; Fradley MG
Curr Treat Options Oncol; 2020 Jun; 21(8):67. PubMed ID: 32607825
[TBL] [Abstract][Full Text] [Related]
18. Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Steele L; George C; Cerio R; O'Toole EA
Clin Exp Dermatol; 2022 Feb; 47(2):488-490. PubMed ID: 34882824
[No Abstract] [Full Text] [Related]
19. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]